These are the stocks posting the largest moves before the bell.Market Insiderread more
CNBC's Mike Santoli breaks down the aggressive buying of "sure things" and shunning of cyclical and policy risk.Trading Nationread more
The Iranian Intelligence Ministry held a briefing on Monday where they announced the alleged spies were Iranian citizens but trained by the CIA.World Newsread more
Equifax will pay at least $575 million, and potentially as much as $700 million, to settle allegations over its massive over 2017 data breach, U.S. regulators said in a...Technologyread more
Facebook has seen an increase in the median number of comments, likes and ads clicked by users on the service from January to July, according to Audience Insights, a Facebook...Technologyread more
Two traders say Boeing's on the path to recovery.Trading Nationread more
In its latest attempt to build market credibility, China on Monday launched the Science and Technology Innovation Board, or "STAR Market," on which 25 companies were listed.China Economyread more
Bridgewater Associates's flagship fund reportedly posted one of its worst first-half performances in two decades.Hedge Fundsread more
The U.S. will likely emerge the winner in a "cold currency war" that is heating up, an expert said.Currenciesread more
Morgan Stanley maintained its overweight rating on Apple's stock and hiked its price target to $247 from $231, heading into the tech giant's third-quarter earnings on July 30.Investingread more
General Electric is scheduled to report second-quarter earnings at the end of the month.Investingread more
CNBC reported Wednesday that Sam Waksal will step aside as chief executive of closely held Kadmon as the company plans to file for an initial public offering. Because of Waksal's ban from serving as an officer of a public company that stemmed from his insider trading charges, his brother, Harlan, is joining the company as president and CEO.
Kadmon confirmed the news in a press release, also noting Sam Waksal would remain chairman, "and will transition from that role in the event that the company elects to pursue an initial public offering."
The two brothers founded and ran ImClone together, with Sam as CEO and Harlan as chief operating officer, among other roles. At Kadmon, Sam will become chief of innovation, science and strategy.
"As we look to the future, it is my goal to ensure that the company is well-positioned to take advantage of value-building corporate, strategic and financial options," Harlan Waksal said in the company's statement.
Kadmon, which is developing drugs for cancer and other diseases, has raised about $500 million in debt and equity. A potential IPO comes amid a record streak in the biotech industry, and investors are likely to have an appetite for the company, said Les Funtleyder, portfolio manager with Esquared Asset Management and author of the book Healthcare Investing.
"Given how well the market's been receiving health-care IPOs this year, especially with late-stage assets, and Kadmon certainly has a fair share of late-stage assets, I think the market would be very receptive to a company like this," Funtleyder said. "ImClone was a very successful company; they brought a cancer drug to market that has actually helped people."
ImClone developed the cancer drug Erbitux, which was approved in 2004 after a rocky development path. It was the rejection of the drug's application by the FDA, in 2001, that was the source of the insider trading scandal involving both Waksal and Stewart. ImClone was sold to Eli Lilly in 2008 for $6.5 billion.
Read MoreShort sellers aiming at biotech
"Given his track record and given the desire for new drugs coming to market, I'd say investors are certainly willing to give him a chance," Funtleyder said. "Certainly the more financial-minded will remember ImClone ultimately got acquired by Lilly; it was very successful and a lot of people made money."
That doesn't mean the path to market won't be complicated.
"It's reasonable to expect that in the comment process of going public, there will be a lot of questions from the SEC about Mr. Waksal's going-forward role and the independence that his brother will exercise in the executive capacity in which he will serve," said Jacob Frenkel, chair of the securities enforcement, white-collar crime and government investigations practice at law firm Shulman, Rogers. "This will be scrutinized."